Chances look good for GSK/HGS anthrax drug on 2nd review
This article was originally published in Scrip
Executive Summary
Things are looking up for the second round at the US FDA for raxibacumab, an experimental inhalational anthrax treatment developed by Human Genome Sciences, now part of GlaxoSmithKline, after agency drug reviewers gave the medicine a mostly positive review.